BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30351860)

  • 1. Clinicopathological and fluorescence in situ hibridisation analysis of primary testicular diffuse large B-cell lymphoma: a single-centre case series.
    Jovanovic MP; Mihaljevic B; Jovanovic P; Jelicic J; Martinovic VC; Jovanović J; Fekete MD; Čekerevac M; Bojanić N
    Pol J Pathol; 2018; 69(2):136-142. PubMed ID: 30351860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
    Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
    Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
    Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
    Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
    Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
    J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary testicular diffuse large B-cell lymphoma: Case series.
    Wang Q; Zheng D; Chai D; Wu S; Wang X; Chen S; Wu L; Cao R; Tao Y
    Medicine (Baltimore); 2020 Mar; 99(12):e19463. PubMed ID: 32195944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
    APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
    Zou D; Yi S; Cui R; Liu W; Li C; Zhong S; Yu Z; Li Z; Lv R; Ru K; Wang H; An G; Xu Y; Qiu L
    BMC Med Genet; 2017 Feb; 18(1):16. PubMed ID: 28209136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
    J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.